Back to Archived News
Medipattern Receives US Patent for Its Core Technology
Wednesday, September 22, 2010
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, is pleased to announced that its core technology, "system and method of computer-aided detection (CAD)," received United States Patent # 7,783,094. The invention comprises the core technology for Medipattern embodied in its Cadenza Platform which is the basis for all Medipattern products. Cadenza is the only cross-modality CAD platform proving that the technology is applicable to breast ultrasound and breast magnetic resonance imaging (MRI) used in aiding physicians to diagnose breast cancer. Cadenza is currently being tuned for use with vascular imaging and has been used in research applications for thyroid and prostate cancer, further establishing Cadenza as the only cross-disease CAD technology platform. The inventors are Jeffrey Collins, President and CEO of Medipattern, Frederic Lachmann, PhD, Chief Technology Officer of Medipattern, and Karén Saghatelyan, Senior Consulting Engineer. The technology is approved or pending in many other countries globally in which the company believes it can capture significant market advantage through the application of this core platform.
The invention relates to computer-aided automatic detection of abnormalities in and analysis of medical images. Medical images are analyzed, to extract and identify a set of features in the image relevant to a diagnosis. The system computes an initial diagnosis based on the set of identified features and a diagnosis model, which are provided to a user for review and modification. A computed diagnosis is dynamically re-computed upon user modification of the set of identified features. Upon a user selecting a diagnosis based on system recommendation, a diagnosis report is generated reflecting features present in the medical image as validated by the user and the user selected diagnosis.
"Patents are granted in recognition of unique, leading-edge technology innovation. We congratulate the entire team at Medipattern for their accomplishment and their contribution to the furtherance of medical science," commented Janet Sterritt, VP of Business Strategy for Medipattern. "Application of Cadenza to Breast Ultrasound Imaging and Breast MRI in the B-CAD and B-CADmri products as well as our research in vascular, prostate and thyroid imaging indicate that the algorithms are quite robust. This technology positions Medipattern as a key innovator in developing products to assist physicians in making better medical diagnoses thereby contributing to increased quality of care for all patients."
About The Medipattern Corporation
Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: www.medipattern.com.
B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Back to Archived News